Table 1. CpG-ODN therapy increases the... | American Society of Hematology

Table 1.

CpG-ODN therapy increases the number of naive and activated T cells

	Cell number per spleen, millions		Fold increase
	CpG-ODN	Neg-ODN	Fold increase
Total CD4⁺	35.4 ± 2.2	9.44 ± 0.95	3.75
CD4⁺CD44^low	18.4 ± 2.4	5.74 ± 0.85	3.21
CD4⁺CD44^high	17.0 ± 2.6	3.70 ± 0.74	4.59
Total CD8⁺	20.9 ± 3.1	5.50 ± 0.85	3.81
CD8⁺CD44^low	12.4 ± 3.0	3.30 ± 0.70	3.76
CD8⁺CD44^high	8.6 ± 0.5	2.20 ± 0.09	3.89

	Cell number per spleen, millions		Fold increase
	CpG-ODN	Neg-ODN	Fold increase
Total CD4⁺	35.4 ± 2.2	9.44 ± 0.95	3.75
CD4⁺CD44^low	18.4 ± 2.4	5.74 ± 0.85	3.21
CD4⁺CD44^high	17.0 ± 2.6	3.70 ± 0.74	4.59
Total CD8⁺	20.9 ± 3.1	5.50 ± 0.85	3.81
CD8⁺CD44^low	12.4 ± 3.0	3.30 ± 0.70	3.76
CD8⁺CD44^high	8.6 ± 0.5	2.20 ± 0.09	3.89

Repeated CpG-ODN administration induces an increase in CD4⁺ and CD8⁺ T-cell numbers. The number of CD44^low (naive) and CD44^high (antigen experienced) CD4⁺/CD3⁺ and CD8⁺/CD3⁺ T cells in spleens for each treatment group was determined by triple-color flow cytometry. The total cell yield was calculated by multiplying the proportion of each cell subset by the total number of live cells obtained per organ. Values represent the means and standard deviations obtained from 3 animals. Results are representative of 3 separate experiments.

View Large

This Feature Is Available To Subscribers Only